GentiBio
Cambridge, Massachusetts, United States · Biotechnology, Health Care, Therapeutics
GentiBio is a leading cell and gene therapy company specializing in engineered regulatory T cells (Tregs) programmed to treat autoimmune and inflammatory diseases.
You have opened 5 full company profiles today. Create an account to keep reading them. Create an account
Key facts
- Headquarters
- Cambridge, Massachusetts, United States
- Employees
- 59
- Industries
- Biotechnology, Health Care, Therapeutics
- Status
- Private
- Website
- http://gentibio.com/
- Company page
Recent activity at GentiBio
- : Gentibio, Inc. secured a $1,150,749 NIH SBIR/STTR award: Development of Tissue Engineered Tregs as a Treatment for Acute Ischemic Stroke
- : GentiBio Appoints Mark Bach, M.D., Ph.D. as Chief Medical Officer
- : Gentibio Announces $157M Series A Financing To Advance Engineered Regulatory T Cells As Transformative Therapeutics With Potential To Restore Immune Tolerance And Durably Treat Autoinflammation
Employee benefit plans
GentiBio files 1 employee benefit plan with the U.S. Department of Labor, including a retirement plan. The next plan year renews in Nov 2026.
About GentiBio: questions and answers
What does GentiBio do?
GentiBio is a leading cell and gene therapy company specializing in engineered regulatory T cells (Tregs) programmed to treat autoimmune and inflammatory diseases.
Where is GentiBio headquartered?
GentiBio is headquartered in Cambridge, Massachusetts, United States.
How many employees does GentiBio have?
GentiBio has about 59 employees.
What is the latest news on GentiBio?
On Jul 08, 2026, Gentibio, Inc. secured a $1,150,749 NIH SBIR/STTR award: Development of Tissue Engineered Tregs as a Treatment for Acute Ischemic Stroke
Source: Fundz records from SEC filings, press releases and company announcements. How Fundz measures data accuracy